Grantham Mayo Van Otterloo & Co. LLC Buys 464,885 Shares of Pfizer Inc. (NYSE:PFE)

Grantham Mayo Van Otterloo & Co. LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 21.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,676,738 shares of the biopharmaceutical company’s stock after purchasing an additional 464,885 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Pfizer were worth $71,014,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC bought a new position in Pfizer during the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer in the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $22.99 on Friday. The firm has a 50 day simple moving average of $25.87 and a two-hundred day simple moving average of $26.76. The stock has a market cap of $130.39 billion, a PE ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $22.95 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PFE. Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.